PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.65%
Both companies show declining cash positions (-7.65% vs GNPX's -16.57%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.65%
Below half of GNPX's -16.57%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of GNPX's -100.00%. David Dodd sees a leaner approach to short-term items.
-5.46%
Below half of GNPX's -17.23%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.35%
Below half GNPX's 52.31%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Non-Current Assets Growth compared to GNPX's zero value, indicating worse performance.
2.60%
Below half of GNPX's 17.17%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Below half of GNPX's -16.11%. Michael Burry sees a potential red flag for stagnation or capital shortage.
41.04%
Less than half of GNPX's -47.81%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.09%
Less than half of GNPX's -31.41%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.41%
Less than half of GNPX's -31.41%. David Dodd sees far fewer liability expansions relative to competitor.
4.74%
Above 1.5x GNPX's 1.11%. Michael Burry suspects heavy new equity expansion or dilution.
-3.50%
Below half GNPX's -13.00%. Michael Burry suspects major net losses or high dividends vs. competitor.
-4.99%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-23.90%
≥ 1.5x GNPX's -15.29%. David Dodd sees stronger capital base growth than competitor.
-5.18%
Below half GNPX's -16.11%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.42%
50-75% of GNPX's 17.47%. Bruce Berkowitz notes comparatively lower net debt expansion.